Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

refametinib

An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
BackgroundPrevious studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
2018
2018
Purpose: Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in combination with sorafenib in patients with… Expand
  • table 1
  • table 2
2017
2017
Purpose The MEK/MAPK pathway is commonly activated in HER2-positive breast cancer, but little investigation of targeting this… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
BackgroundActivating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2016
2016
Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2015
2015
Purpose: To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2014
Highly Cited
2014
Purpose: There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2014
2014
2588 Background: Dual inhibition of the PI3K and MAPK signaling pathways is a promising strategy for optimal anticancer therapy… Expand
Review
2013
Review
2013
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
2013
2013
OBJECTIVE The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY… Expand